Getinge AB is acquiring 100% of the equity in fluorescence imaging company Fluoptics SAS, a company using the technology as an aid to surgery. Getinge will, through its subsidiary Getinge Infection Control SAS, acquire all outstanding shares in Fluoptics and will pay around $27 million in cash on closing the deal.
For brain surgeons, the shift is the sticking point. When a surgeon opens the cranium to remove a tumor, the brain moves as much as 1 cm, making much of the pre-operative mapping of the tumor essentially useless. While the bulk of a lesion can be identified by its density, the tendrils blend into the surrounding tissue – and taking excess margins means more brain damage. Designs for Vision Inc.’s bright idea, a headlamp that illuminates a fluorescing tumor with a laser light, makes brain surgery quicker, safer and more accurate.
Onlume Inc. has secured $7 million in a series A round led by Cambridge Investment Group. Other investors participating in the round included WARF Ventures (Wisconsin Alumni Research Foundation) and Wisconsin Investment Partners. The proceeds will support the commercial launch of the company’s FDA-cleared fluorescence-guided surgery (FGS) imaging system.
